# EDGAR Filing Document

**Accession Number:** 0001438133
**File Stem:** 0001438133-25-000190
**Filing Date:** 2025-11
**Character Count:** 10174
**Document Hash:** 51ecd99dd279c6592390c304419db865
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001438133-25-000190.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001438133-25-000190

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251107

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TANDEM DIABETES CARE INC
- **CENTRAL INDEX KEY:** 0001438133
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 204327508
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36189
- **FILM NUMBER:** 251469561

**BUSINESS ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **CITY:** San Diego
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 858-366-6900

**MAIL ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **CITY:** San Diego
- **STATE:** CA
- **ZIP:** 92130

?xml version='1.0' encoding='ASCII'? tndm-20251107

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

____________________________

**FORM 8-K**

____________________________

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of The Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): November 7, 2025**

**Tandem Diabetes Care, Inc.** 

**(Exact name of registrant as specified in its charter)** 

____________________________

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **001-36189** | **20-4327508** |
| **(State or other jurisdiction<br>of incorporation)** | **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer <br> Identification No.)** |
| **12400 High Bluff Drive** | **12400 High Bluff Drive** | | **92130** |
| **San Diego** | **California** | | **(Zip Code)** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | | |

---

**Registrant's telephone number, including area code: (858) 366-6900** 

**N/A** 

**(Former name or former address, if changed since last report)** 

____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<u>Title of Each Class</u>** | **<u>Trading Symbol</u>** | **<u>Name of Each Exchange on Which Registered</u>** |
| **Common Stock, par value $0.001 per share** | **TNDM** | **NASDAQ Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

____________________________

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) Appointment of Sandra Beaver as Director

On November 7, 2025, the Board of Directors (the "Board") of Tandem Diabetes Care, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the size of the Board from eight to nine directors and appointed Sandra Beaver, age 48, to serve as a member of the Board, with a term of office that expires at the Annual Meeting of Stockholders of the Company to be held in 2026. Additionally, the Board appointed Ms. Beaver as a member of the Audit Committee of the Board (the "Audit Committee") and the Cybersecurity and Data Privacy Committee of the Board (the "C/D/P Committee").

In accordance with the Company's Non-Employee Director Compensation Policy (the "Policy"), Ms. Beaver received an initial restricted stock unit ("RSU") award for 20,242 shares of the Company's common stock, reflecting a value of $300,000, as calculated in accordance with the terms of the Policy. The RSU vests as to one-third of the total shares on each anniversary of the grant date, subject to Ms. Beaver's continuous service as a director. Ms. Beaver is also eligible to receive an annual retainer of $60,000 for her service on the Board, additional annual retainers of $11,000 for her service on the Audit Committee and $6,000 for her service on the C/D/P Committee, and an annual RSU award for a number of shares with an aggregate value of approximately $180,000, as calculated in accordance with the terms of the Policy, and granted on the date of each Annual Meeting of Stockholders of the Company.

The Company will enter into its standard form of indemnity agreement for directors and officers with Ms. Beaver, a copy of which is filed as Exhibit 10.14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

**Item 9.01 Financial Statements and Exhibits.** 

(d) Exhibits.

---

| | |
|:---|:---|
| **<u>Number</u>** | **<u>Description</u>** |
| 99.1 | <u>[Press release of Tandem Diabetes Care, Inc. dated November 12, 2025](exhibit991-pressreleasexbo.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Tandem Diabetes Care, Inc. | Tandem Diabetes Care, Inc. |
| By: | /s/ SHANNON M. HANSEN |
|  | Shannon M. Hansen |
|  | Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary |

---

Date: November 12, 2025

## Exhibit 99.1

Exhibit 99.1

![tandemhorizontallogonewrgb.jpg](tandemhorizontallogonewrgb.jpg)

**<u>FOR IMMEDIATE RELEASE</u>**

**Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors**

**SAN DIEGO, November 12, 2025** - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee.

"We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance executive whose experience and insight will be invaluable in helping guide our growth, particularly as we deliver transformative digital health solutions, while scaling efficiently and reaching new markets and geographies."

"I look forward to joining Tandem's Board of Directors," said Ms. Beaver. "As a global financial and healthcare leader, I see tremendous opportunity for Tandem to continue driving innovation and executing against their strategy to create long-term, sustainable growth that benefits the diabetes community and shareholders alike."

Ms. Beaver has more than 20 years of strategic and operational finance experience globally and across many industries including healthcare, medical devices, gaming, enterprise technology and manufacturing. Ms. Beaver is the CFO at Lyra Health, a leading provider of mental health solutions, overseeing finance, accounting, investor relations, facilities, procurement and corporate development. Before starting this role in June 2025, she served as CFO at Evolus, a publicly traded medical aesthetics company, for three years. Before Evolus, Ms. Beaver held senior finance positions at global data and technology company, Experian, and global gaming company, IGT. Ms. Beaver holds a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.

**About Tandem Diabetes Care, Inc.** 

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit <u>tandemdiabetes.com</u>.

Follow @TandemDiabetesCare on TikTok and @TandemDiabetes on Facebook, Instagram, LinkedIn, and X.

<br>©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

**Media Contact:**

858-366-6900

<u>media@tandemdiabetes.com</u>

**Investor Contact:**

858-366-6900

<u>IR@tandemdiabetes.com</u>

<br>